MCC-950

• Background:

  NLRP3 (MCC950) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1(1). Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes(2). Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations3. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model)(3). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome(4). A valuable new tool for exploring the pathophysiology of NLRP3. It may contribute to additional alpha synuclein aggregation and cell loss in PD (5).

• Description:

  NLRP3 inflammasome activation inhibitor

• Product Name Alternative:

  N-[[ (1,2,3,5,6,7-Hexahydro-s-indacen-4-yl) amino]carbonyl]-4- (1-hydroxy-1-methylethyl) -2-furansulfonamide sodium salt; CRID3; CP-456773 sodium salt

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Growth Factors | TNF | Neuroscience | Neurodegeneration | Parkinson's Disease | Synuclein| Cancer

• Purity:

  >98% (HPLC) ; NMR (Conforms)

• Weight:

  0.005

• Format:

  White powder

• Solubility:

  May be dissolved in water (30 mg/ml): or DMSO (40 mg/ml)

• Molecular Formula:

  C20H23N2O5S ∙ Na

• Molecular Weight:

  426.5

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Laliberte R.E. et al. (2003) J. Biol. Chem. 278(19):16567-78. 2. Coll R.C., et al. (2011) PLoS One. 6(12):e29539. 3. Coll R.C., et al. (2015) Nat. Med. 21(3):248-255. 4. Kaneko N., et al. (2015) J. Immunol. Methods. 426:76-81. 5. Nguyen L., et al. (2022) J Parkinsons Dis. 12(7): 2117-2133.

• CAS Number:

  256373-96-3